CASI Pharmaceuticals, Inc. CASIF
Set alert
0.11 USD -0.01 -10.64%
As of Nov 3, 9:30 AM ET
0.105 Day range 0.105
0.05 52-week range 1.48
- YTD
- -87.65%
- 1 year
- -92.45%
- Open
- 0.105
- Prev close
- 0.1175
- Mkt cap
- 2.16M
- Vol
- 140
- Avg vol
- 2.15K
- EPS
- -2.00
- P/E
- 0.00
More statistics
- Low
- 0.105
- High
- 0.105
3M chart
Signals (36)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 30, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
Newest 20 of 36.
News
- What Drove CASI Pharmaceuticals' 24% Rise After Hours?
- CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
- CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
- CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
- CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
- CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
- CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
- CASI Pharmaceuticals Announces Changes in Board Governance
- CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
- CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
Your note
Sign in to keep a note on CASIF — it syncs with the Stock Master app.